The Phase 1 proof-of-concept study analyzed whole genome and limited clinical data from 4,600 GLP-1 RA patients and demonstrated that we can: Identify strong and weak responders based on genetic signatures Quantitatively predict efficacy using BMI and HbA1c change Detect over 2,500 genetic signatures mapping to 1,100 genes Identify 15 major biological mechanisms driving response This is the first time detailed mechanistic efficacy signals have been shown directly within a GLP-1-treated real-world population at this level of resolution
You may be a candidate if: Your BMI is 30 or higher
Lucie, designed to enhance immune function, optimize hormone balance, and strengthen bone health
Within that segment, the bank expects Eli Lillys pill to have a 60% share, or roughly $13.6 billion, of the daily oral segment
Additionally, future research should explore whether adjunctive therapies, such as resistance training or bone-specific pharmacologic interventions, could counteract potential bone resorption associated with weight loss or be superior to GLP-1s